The risks of major osteoporotic fractures in patients with schizophrenia: A population-based 10-year follow-up study

Schizophrenia Research

Volumn 159, Issue 2-3, 2014, Pages 322-328

  Tsai, Kuan Yi ^a,b   Lee, Ching Chih ^c,d   Chou, Yu Mei ^e   Shen, Shih Pei ^a   Su, Chao Yueh ^f   Wu, Hung Chi ^a   Huang, Min Wei ^g   Shie, Jia Pei ^a   Chou, Frank Huang Chih ^a,b  

^a Kaohsiung Municipal Kai Syuan Psychiatric Hospital   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

^g TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Major osteoporotic fracture; National health insurance research database (NHIRD); Proportion of days covered (PDC); Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SURVIVAL RATE; TAIWAN;

EID: 84922577279     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.09.032     Document Type: Article

References (47)

1. Abraham G., Halbreich U., Friedman R.H., Josiassen R.C. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr. Res. 2003, 59:17-18.
2. Bessette L., Ste-Marie L.G., Jean S., et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos. Int. 2008, 19:79-86.
3. Bolton J.M., Metge C., Lix L., Prior H., Sareen J., Leslie W.D. Fracture risk from psychotropic medications: a population-based analysis. J. Clin. Psychopharmacol. 2008, 28:384-391.
4. Bonnot O., Inaoui R., Raffin-Viard M., Bodeau N., Coussieu C., Cohen D. Children and adolescents with severe mental illness need vitamin D supplementation regardless of disease or treatment. J. Child Adolesc. Psychopharmacol. 2011, 21:157-161.
5. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
6. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 1987, 40:373-383.
7. Chou F.H., Tsai K.Y., Su C.Y., Lee C.C. The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr. Res. 2011, 129:97-103.
8. Chou F.H., Tsai K.Y., Chou Y.M. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: a nine-year follow-up study. J. Psychiatr. Res. 2013, 47(4):460-466.
9. Coodin S. Body mass index in persons with schizophrenia. Can. J. Psychiatry 2001, 46:549-555.
10. Dempster D.W. Osteoporosis and the burden of osteoporosis related fractures. Am. J. Manage Care 2011, 17(Suppl. 6):S164-S169.
11. Edlund M.J., Conrad C., Morris P. Accidents among schizophrenic outpatients. Compr. Psychiatry 1989, 30:522-526.
12. Fechtenbaum J., Cropet C., Kolta S., Verdoncq B., Orcel P., Roux C. Reporting of vertebral fractures on spine X-rays. Osteoporos. Int. 2005, 16(12):1823-1826.
13. Gregg E.W., Yaffe K., Cauley J.A., Rolka D.B., Blackwell T.L., Narayan K.M., Cummings S.R. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch. Intern. Med. 2000, 160:174-180.
14. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
15. Halbreich U., Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr. Bull. 1996, 22:447-454.
16. Halbreich U., Rojansky N., Palter S., Hreshchyshyn M., Kreeger J., Bakhai Y., Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 1995, 57:485-491.
17. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003, 28(Suppl. 1):53-67.
18. Hess L.M., Raebel M.A., Conner D.A., Malone D.C. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann. Pharmacother. 2006, 40:1280-1288.
19. Howard L., Kirkwood G., Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br. J. Psychiatry 2007, 190:129-134.
20. Hugenholtz G.W., Heerdink E.R., van Staa T.P., Nolen W.A., Egberts A.C. Risk of hip/femur fractures in patients using antipsychotics. Bone 2005, 37:864-870.
21. Kanis J.A., Hans D., Cooper C., et al. Interpretation and use of FRAX in clinical practice. Osteoporos. Int. 2011, 22:2395-2411.
22. Kishimoto T., De H.M., Carlson H.E., Manu P., Correll C.U. Osteoporosis and fracture risk in people with schizophrenia. Curr. Opin. Psychiatry 2012, 25:415-429.
23. Kruger M.C., Kruger I.M., Wentzel-Viljoen E., Kruger A. Urbanization of black South African women may increase risk of low bone mass due to low vitamin D status, low calcium intake, and high bone turnover. Nutr. Res. 2011, 31:748-758.
24. Lai S.W., Liao K.F., Lai H.C., Tsai P.Y., Lin C.L., Chen P.C., Sung F.C. Risk of major osteoporotic fracture after cardiovascular disease: a population-based cohort study in Taiwan. J. Epidemiol. 2013, 23(2):109-114.
25. Lin Y.C., Pan W.H. Bone mineral density in adults in Taiwan: results of the Nutrition and Health Survey in Taiwan 2005-2008 (NAHSIT 2005-2008). Asia Pac. J. Clin. Nutr. 2011, 20:283-291.
26. Lin C.H., Huang K.H., Chang Y.C., et al. Clozapine protects bone mineral density in female patients with schizophrenia. Int. J. Neuropsychopharmacol. 2012, 15(7):897-906.
27. Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum. Psychopharmacol. 2010, 25:281-297.
28. McCreadie R.G. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry 2003, 183:534-539.
29. Meadows E.S., Mitchell B.D., Bolge S.C., Johnston J.A., Col N.F. Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. BMC Womens Health 2012, 12:1.
30. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br. J. Psychiatry 2004, 184:503-508.
31. Misra M., Papakostas G.I., Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin. Psychiatry 2004, 65:1607-1618.
32. Molitch M.E. Medication-induced hyperprolactinemia. Mayo Clin. Proc. 2005, 80:1050-1057.
33. Naidoo U., Goff D.C., Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003, 28(Suppl. 2):97-108.
34. Neuhaus V., King J., Hageman M.G., Ring D.C. Charlson comorbidity indices and in-hospital deaths in patients with hip fractures. Clin. Orthop. Relat. Res. 2013, 471(5):1712-1719.
35. Piscitelli P., Brandi M.L., Chitano G., et al. Epidemiology of fragility fractures in Italy. Clin. Case Miner. Bone Metab. 2011, 8:29-34.
36. Riggs B.L., Melton L.J. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995, 17(5 Suppl.):505S-511S.
37. Rubin K.H., Abrahamsen B., Friis-Holmberg T., et al. Comparison of different screening tools (FRAX(R), OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. Bone 2013, 56(1):16-22.
38. Rudang R., Mellstrom D., Clark E., Ohlsson C., Lorentzon M. Advancing maternal age is associated with lower bone mineral density in young adult male offspring. Osteoporos. Int. 2012, 23:475-482.
39. Sasser A.C., Rousculp M.D., Birnbaum H.G., Oster E.F., Lufkin E., Mallet D. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Women's Health Issues 2005, 15(3):97-108.
40. Sikka R., Xia F., Aubert R.E. Estimating medication persistency using administrative claims data. Am. J. Manage Care 2005, 11:449-457.
41. Sleath B., Domino M.E., Wiley-Exley E., Martin B., Richards S., Carey T. Antidepressant and antipsychotic use and adherence among Medicaid youths: differences by race. Community Ment. Health J. 2010, 46:265-272.
42. Smink B.E., Egberts A.C., Lusthof K.J., Uges D.R., de Gier J.J. The relationship between benzodiazepine use and traffic accidents: a systematic literature review. CNS Drugs 2010, 24:639-653.
43. Stubbs B., Zapata-Bravo E., Haw C. Screening for osteoporosis: a survey of older psychiatric inpatients at a tertiary referral centre. Int. Psychogeriatr. 2009, 21:180-186.
44. Tarantino U., Capone A., Planta M., et al. The incidence of hip, forearm, humeral, ankle, and vertebral fragility fractures in Italy: results from a 3-year multicenter study. Arthritis Res. Ther. 2010, 12:R226.
45. Tsai K.Y., Lee C.C., Chou Y.M., Su C.Y., Chou F.H. The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study. Schizophr. Res. 2012, 138:41-47.
46. Vanasse A., Courteau J., Cohen A.A., Orzanco M.G., Drouin C. Rural-urban disparities in the management and health issues of chronic diseases in Quebec (Canada) in the early 2000s. Rural Remote Health 2010, 10(4):1548.
47. Vestergaard P., Rejnmark L., Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos. Int. 2006, 17:807-816.